Our data support the use of new therapeutic approaches based on the inhibition of Erk2 signaling pathway that will improve the current therapy of CML, even in the advanced stage of the disease were overexpression of Bcr/Abl is a common feature. This evidence concerns the gene MAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive.